Ratings Nahdi Medical Company

Equities

4164

SA15HG521213

End-of-day quote Saudi Arabian S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
136 ^SAR	+0.44%		-4.09%	-0.73%

Mar. 18	Nahdi Medical Company Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 18	Nahdi Medical Posts Higher FY23 Net Profit, Revenue	MT

Summary

The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company appears highly valued given the size of its balance sheet.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NAHDI MEDICAL COMPANY	-0.73%	4.69B		D-
JD HEALTH INTERNATIONAL INC.	-29.67%	10.84B		B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-28.54%	6.06B		B
YIFENG PHARMACY CHAIN CO., LTD.	+7.42%	6.04B		C
MATSUKIYOCOCOKARA & CO.	-11.41%	5.86B		C+
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+52.19%	4.29B	-	C
CLICKS GROUP LIMITED	-12.31%	3.61B		B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-13.25%	3.33B		C-
WELCIA HOLDINGS CO., LTD.	-6.93%	3.01B		C-
REDCARE PHARMACY NV	-2.36%	2.8B		B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes